Respiratory Syncytial Virus (RSV) Vaccine

    Not Recruiting
  • sponsor
Updated on 31 January 2022


This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to assess the safety, immunogenicity, and efficacy of RSVpreF or placebo (1:1 randomization) in adults. This will be a global study that will span multiple RSV seasons.


  • Condition: Vaccine
  • Drug: RSVpreF
  • Clinical Trial Identifier: NCT05035212
  • Sponsor: Pfizer

Condition Vaccines, Respiratory Syncytial Virus, vaccine, rsv, Respiratory Syncytial Virus (RSV)
Clinical Study IdentifierTX285147
Last Modified on31 January 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note